A61P 5 - Drugs for disorders of the endocrine system

Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
11/2002
11/14/2002	WO2002090530A2 Kinases and phosphatases
11/14/2002	WO2002090355A1 N-aroyl cyclic amines
11/14/2002	WO2002089802A2 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
11/14/2002	WO2002089800A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002	WO2002064550A8 Glucocorticoid receptor modulators
11/14/2002	WO2002055012A3 Therapeutic heterocyclic compounds
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2001097787A3 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
11/14/2002	US20020169292 Human glycoprotein hormone for use in the prevention and treatment of metabolic and sexual disorders
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169198 Agonists of the progesterone receptor; contraceptives, hormone replacement therapy and treating menopause symptoms
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169165 Substituted bicyclic derivatives for the treatment of abnormal cell growth
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020168380 Moderating immunology response
11/14/2002	US20020168344 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2435142A1 Kinases and phosphatases
11/14/2002	CA2385809A1 Alkylamide compounds
11/13/2002	EP1255835A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255819A2 Human kinases
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255738A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
11/13/2002	EP1255557A1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
11/13/2002	EP1255553A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers
11/13/2002	EP1255536A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase
11/13/2002	EP0735863B1 Accelerated release composition containing bromocriptine
11/13/2002	CN1379817A Composition and methods for increasing cholesterol efflux and raising HDL using ATP binding cassettte ttansporter protein ABC1
11/13/2002	CN1379766A Benzoic acid derivatives for treatment of diabetes mellitus
11/13/2002	CN1379675A 24-hydroxyvitamin D, analogs and use thereof
11/13/2002	CN1379666A Non-peptide GnRH agents, methods and intermediates for their preparation
11/12/2002	US6479545 Formulation for menopausal women
11/12/2002	US6479540 Compositions of tocol-soluble therapeutics
11/12/2002	US6479538 Cyclic ether vitamin D3 compounds, 1α(OH)3-EPI-vitamin D3 compounds and uses thereof
11/12/2002	US6479476 Treating menopausal symptoms and osteoporosis in female warm-blooded animals
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088182A1 Nove g protein-coupled receptor protein and dna thereof
11/07/2002	WO2002088167A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	WO2002088143A2 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088139A1 6h-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088115A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	WO2002088090A2 Pyrazole derived kinase inhibitors
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002087626A1 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
11/07/2002	WO2002087616A1 Preventives for postoperative recurrence of premenopausal breast cancer
11/07/2002	WO2002087606A2 Modulators of the hypocretin system and methods of screening therefor
11/07/2002	WO2002087605A2 Modified fvii in treatment of ards
11/07/2002	WO2002087573A1 Crf receptor antagonists
11/07/2002	WO2002087562A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	WO2002087546A2 Method for manufacturing a low dose pharmaceutical composition
11/07/2002	WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	WO2002047693A3 Steroid hormone products comprising a stabilizing agent in non-crystalline form
11/07/2002	WO2001036365A3 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
11/07/2002	WO2000064420A3 Compositions and methods for treating amyloidosis using sulphonate derivatives
11/07/2002	US20020166135 Modulation of preferential aspects of nervous system; obtain human, administer modulator, monitor expression of preferential neuropeptides in brain
11/07/2002	US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002	US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002	US20020165343 Growth hormone secretagogues
11/07/2002	US20020165226 Estrogen receptor modulators
11/07/2002	US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002	US20020165211 Aqueous suspension of Fluticasone furoate; respiratory tract disorders; asthma, COPD; antiinflammatory, antiallergen; nasal inhaler
11/07/2002	US20020165209 Low dose estrogen interrupted hormone replacement therapy
11/07/2002	US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2446497A1 Crf receptor antagonists
11/07/2002	CA2445839A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	CA2445811A1 Modified fvii in treatment of ards
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002	CA2445343A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2444727A1 Agents for preventing postoperative recurrence of premenopausal breast cancer
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/06/2002	EP1254662A2 Methods and kits for treating depression or preventing deterioration of cognitive function
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254236A2 Drug metabolizing enzymes
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254175A1 Human cystine knot polypeptide
11/06/2002	EP1254134A2 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
11/06/2002	EP1254132A1 Food product and process
11/06/2002	EP1254130A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/06/2002	EP1254123A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
11/06/2002	EP1254114A2 Melanocortin receptor agonists and antagonists
11/06/2002	EP1254113A1 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
11/06/2002	EP1254106A1 Calcilytic compounds
11/06/2002	EP1253933A2 Method for treating thyroid disorders
11/06/2002	EP1253931A2 Utilization of protein kinase inhibitor alpha
11/06/2002	EP1253925A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
11/06/2002	EP1253922A2 Statin-type bone growth stimulators
11/06/2002	CN1378535A 四氢喹啉衍生物 Tetrahydroquinoline derivative
11/06/2002	CN1377880A Compound for curing vascular complication, its preparing method and treating use
11/06/2002	CN1093852C 维生素ｄ酰胺衍生物 Amide derivatives of vitamin d

1 ... 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 ... 290